Today: 21 May 2026
RTX stock today: Pratt & Whitney settlement in focus as Wall Street shuts for New Year’s Day
2 January 2026
2 mins read

RTX stock today: Pratt & Whitney settlement in focus as Wall Street shuts for New Year’s Day

NEW YORK, January 1, 2026, 18:48 ET — Market closed

  • RTX shares last closed down 0.33% at $183.40 on Dec. 31.
  • Pratt & Whitney Canada settled an antitrust lawsuit over used engine sales, a court filing showed.
  • Investors next watch Friday’s reopen, early-January U.S. data and RTX’s expected late-January results.

RTX’s Pratt & Whitney Canada unit has settled an antitrust lawsuit accusing it of blocking competition in sales of used regional aircraft engines and parts, a court filing showed. RTX shares (RTX.N) last closed down 0.33% at $183.40 on Dec. 31, the final session of 2025. The plaintiff, Universal Turbine Parts, had sought more than $150 million in damages; settlement terms were not disclosed.

The case matters because it sits in the “aftermarket” — the maintenance, repairs and spare-parts business that follows an engine’s initial sale. That segment can generate steady, high-margin cash flows for aerospace suppliers.

Investors are watching for any sign that the settlement results in a one-time charge or changes to how engines and parts reach third-party buyers. If disclosure comes, it is more likely to surface in filings or during the next earnings update than in day-to-day trading.

Broader risk appetite was soft in the last session of the year, when the S&P 500 fell 0.74%, the Nasdaq dropped 0.76% and the Dow ended down 0.63%, Reuters reported. “I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters also noted thin holiday trading conditions and that U.S. markets were closed on Thursday for New Year’s Day. Reuters

RTX traded between $182.64 and $184.40 on Dec. 31, with about 2.64 million shares changing hands, according to Yahoo Finance historical data. The stock’s latest close left it below its recent 52-week high of $188.00, based on Investing.com data.

Peers also finished lower in the year’s final session, with Lockheed Martin down 0.89% and Northrop Grumman off 0.76%, according to a MarketWatch roundup of defense names.

On the news flow, the Pentagon said Raytheon Co., an RTX business, was among awardees on a Defense Microelectronics Activity contract with a program ceiling of $25.357 billion. The award is an “indefinite-delivery/indefinite-quantity” contract, meaning it sets terms and a maximum value, but work and funding come through later task orders. U.S. Department of War

What traders are watching now is simple: any follow-on disclosure from the settlement, and whether the defense sector resumes its bid when cash equities reopen on Friday. Contract headlines can move sentiment day-to-day, but earnings and guidance tend to drive the bigger resets.

Before the next session on Jan. 2, investors have an eye on the ISM manufacturing PMI, scheduled for 10:00 a.m. ET. The PMI is a survey-based gauge of factory activity that can shift rate expectations and cyclicals in early January trading.

The next major macro test is the U.S. employment report for December, due Jan. 9, according to the Bureau of Labor Statistics’ release calendar. Bond yields often react sharply to payrolls data, and rate moves can feed into the valuation of large industrials.

Company-specific attention is building toward RTX’s next quarterly report, expected around Jan. 27, based on historical reporting patterns tracked by Zacks. That timing overlaps with the Federal Reserve’s Jan. 27–28 policy meeting, raising the odds that earnings headlines compete with interest-rate messaging in the same week.

On the chart, traders will be watching whether RTX holds above the $182.64 session low from Dec. 31. A move back through the $184–$185 area would signal buyers returning after the year-end drift.

Stock Market Today

  • Analyst Revises MongoDB Outlook After Sharp 22% Stock Decline
    May 20, 2026, 11:08 PM EDT. An analyst shifted to a more favorable view on MongoDB (NASDAQ: MDB) after its stock plunged 22% on March 3, 2026, despite better-than-expected fiscal Q4 results. The company reported $695 million revenue, up 27% year-over-year, with Atlas cloud revenue hitting a $2 billion annual run rate. However, cautious fiscal 2027 guidance projecting 16-18% revenue growth-below expectations-triggered the drop and a Baird price target cut from $500 to $260. The analyst now highlights MongoDB's strong business fundamentals, including a 23% adjusted operating margin and leading position in document databases, which support cloud-native applications. The initial high valuation and AI premium correction have shifted risk perceptions, revealing a steadier business amid recent market volatility.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Coca-Cola stock (KO) sits near $70 as New Year’s Day shuts markets — what Wall Street watches next
Previous Story

Coca-Cola stock (KO) sits near $70 as New Year’s Day shuts markets — what Wall Street watches next

Tesla stock ends 2025 lower as Musk charity share gift surfaces ahead of deliveries
Next Story

Tesla stock ends 2025 lower as Musk charity share gift surfaces ahead of deliveries

Go toTop